frizzled class receptor 9Genealiases: CD349 · FZD3
Q-omics provides the consensus-scored FZD9 profile across patient tissues and cancer cell-line models. FZD9 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, FZD9 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, FZD9 RNA expression shows 17,437 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight THCA, and LSCC as cancer lineages where FZD9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FZD9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FZD9 survival associations across molecular data types. FZD9 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FZD9 RNA expression–survival associations across cancer types. High FZD9 expression shows unfavorable associations in BLCA and STAD, but favorable associations in THCA, KIRC, UCS and OV. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for FZD9 RNA expression.
This table summarizes FZD9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FZD9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FZD9 shows lower tumor expression in THCA and BRCA and higher tumor expression in UCEC, LUSC, LUAD and LIHC. The THCA box plot shows higher FZD9 RNA expression in normal versus tumor tissue (log2 FC = −0.642, t-test p < 0.001).
This table shows molecular features associated with FZD9 in patient tissues and cancer cell lines. In patient samples, FZD9 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FZD9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
